Cooperative Agreement W81XWH2220026

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $781,718 to Loyola University of Chicago's Health Sciences Campus to develop a novel T cell-based vaccine to prevent Dengue virus (DENV) and Zika virus (ZIKV) infection. The researchers aim to design a vaccine that targets the ZIKV non-structural protein 3 (NS3) and uses ubiquitin and gene rearrangement strategies to...

The University of Hawaii at Manoa was awarded a $1,170,041 project grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant, with a performance period from August 1, 2024 to June 30, 2029, aims to understand the long-term safety and effectiveness of the Dengvaxia dengue vaccine in the Philippines. The research project will determine the baseline dengue virus serostatus of Dengvaxia recipients,...

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $1,211,704.00 in funding to Emory University to conduct comprehensive studies on the pathogenesis of severe disease during primary dengue infections. The research aims to determine differences in immune responses between severe primary and secondary dengue infections, including analyses of innate immunity,...

This $299,969 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), is focused on evaluating a mosquito salivary protein, AGBR1, as a vaccine candidate against Chikungunya virus. The project aims to perform comparative assessments of different AGBR1 vaccine formulations, including recombinant protein and mRNA-LNP versions, to determine their protective efficacy against Chikungunya...

This $280,769 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to develop neutralizing antibodies against the Machupo virus, a New World arenavirus. The project utilizes an innovative stabilized-trimer immunogen to identify and characterize antibodies that target critical sites on the viral surface glycoprotein beyond the receptor-binding site. This work builds on prior success...

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $250,796 to support planning activities for a clinical trial to assess the safety, immunogenicity, and efficacy of the PFSPZ-LARC2 malaria vaccine in malaria-exposed adults and children in Burkina Faso. The planning activities include developing the clinical trial protocol, informed consent forms, data management...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $760,318 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of California, Davis (UC Davis) to develop recombinant enhanced antiviral sensors (REAVRS) that can broadly inhibit known and emerging viruses. The grant aims to generate optimized REAVR proteins, identify virus-induced promoters in mosquito cells, and engineer REAVR-expressing mosquitoes to test their...

This Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop an effective HIV vaccine regimen that elicits both broadly neutralizing antibodies and high-quality T-cell responses. The $7,105,240 award supports a 5-year research program with the University of California, Davis as the prime recipient. The program includes three main projects: Project 1 will examine...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $490,396 Cooperative Agreement under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Scripps Research Institute in La Jolla, CA. The award supports the development of a novel live-attenuated vaccine platform against Lassa fever, a viral hemorrhagic fever endemic to West Africa. The key objectives are to comprehensively characterize the safety, immunogenicity, and protective efficacy of a...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will provide $2,178,000 to develop a "tunable nanophage platform" for rapid vaccine development against emerging infectious diseases, including SARS-CoV-2 variants and pre-emergent SARS-like coronaviruses. The key products to be delivered under this award include engineered "second generation" nanophages...